Keywords
Last Name
Institution

Steven A. Atlas

TitleASSOCIATE PROFESSOR
InstitutionMount Sinai
DepartmentMedicine
Address

     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Mukete BN, Atlas SA. Implications of changes in plasma asymmetric dimethylarginine during treatment of hypertension. Curr Hypertens Rep. 2011 Dec; 13(6):406-8.
      View in: PubMed
    2. Vongpatanasin W, Kario K, Atlas SA, Victor RG. Central sympatholytic drugs. J Clin Hypertens (Greenwich). 2011 Sep; 13(9):658-61.
      View in: PubMed
    3. Atlas SA. Aldosterone to renin ratio as a predictor of diuretic response. Curr Hypertens Rep. 2010 Dec; 12(6):395-8.
      View in: PubMed
    4. Almendral JL, Shick V, Rosendorff C, Atlas SA. Association between transforming growth factor-beta(1) and left ventricular mass and diameter in hypertensive patients. J Am Soc Hypertens. 2010 May-Jun; 4(3):135-41.
      View in: PubMed
    5. Atlas SA, Patel SS. Vitamin D levels and the risk of hypertension. Curr Hypertens Rep. 2007 Dec; 9(6):447-9.
      View in: PubMed
    6. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007 Oct; 13(8 Suppl B):9-20.
      View in: PubMed
    7. Mangat S, Atlas SA. Benefits of renin-angiotensin system blockade in advanced renal insufficiency. Curr Hypertens Rep. 2006 Dec; 8(6):443-5.
      View in: PubMed
    8. Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, Alderman MH, Atlas SA, Basile JN, Cuyjet AB, Dart R, Felicetta JV, Grimm RH, Haywood LJ, Jafri SZ, Proschan MA, Thadani U, Whelton PK, Wright JT. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006 Sep; 48(3):374-84.
      View in: PubMed
    9. Dolgilevich SM, Siri FM, Atlas SA, Eng C. Changes in collagenase and collagen gene expression after induction of aortocaval fistula in rats. Am J Physiol Heart Circ Physiol. 2001 Jul; 281(1):H207-14.
      View in: PubMed
    10. Atlas SA, Rosendorff C. The renin-angiotensin system--from Tigerstedt to Goldblatt to ACE inhibition and beyond. Mt Sinai J Med. 1998 Mar; 65(2):81-6.
      View in: PubMed
    11. Atlas SA. The renin-angiotensin system revisited: classical and nonclassical pathway of angiotensin formation. Mt Sinai J Med. 1998 Mar; 65(2):87-96.
      View in: PubMed
    12. Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan ED, Sos TA, Atlas SA, Müller FB, Acevedo R, Ulick S, Laragh JH. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med. 1994 Dec 1; 121(11):877-85.
      View in: PubMed
    13. Ulick S, Blumenfeld JD, Atlas SA, Wang JZ, Vaughan ED. The unique steroidogenesis of the aldosteronoma in the differential diagnosis of primary aldosteronism. J Clin Endocrinol Metab. 1993 Apr; 76(4):873-8.
      View in: PubMed
    14. de Simone G, Devereux RB, Camargo MJ, Volpe M, Wallerson DC, Atlas SA, Laragh JH. In vivo left ventricular anatomy in rats with two-kidney, one clip and one-kidney, one clip renovascular hypertension. J Hypertens. 1992 Aug; 10(8):725-32.
      View in: PubMed
    15. Gahnem F, Sealey JE, Atlas SA, Laragh JH. Inhibition of human renin by rat plasma. Rat angiotensinogen is a competitive inhibitor of the human renin-substrate interaction. Am J Hypertens. 1992 Aug; 5(8):495-501.
      View in: PubMed
    16. de Simone G, Devereux RB, Roman MJ, Ganau A, Chien S, Alderman MH, Atlas S, Laragh JH. Gender differences in left ventricular anatomy, blood viscosity and volume regulatory hormones in normal adults. Am J Cardiol. 1991 Dec 15; 68(17):1704-8.
      View in: PubMed
    17. de Simone G, Devereux RB, Chien S, Alderman MH, Atlas SA, Laragh JH. Relation of blood viscosity to demographic and physiologic variables and to cardiovascular risk factors in apparently normal adults. Circulation. 1990 Jan; 81(1):107-17.
      View in: PubMed
    18. Roman MJ, Devereux RB, Atlas SA, Pini R, Ganau A, Hochreiter C, Niles NW, Borer JS, Laragh JH. Relationship of atrial natriuretic factor to left ventricular volume and mass. Am Heart J. 1989 Dec; 118(6):1236-42.
      View in: PubMed
    19. Ganau A, Devereux RB, Atlas SA, Pecker M, Roman MJ, Vargiu P, Cody RJ, Laragh JH. Plasma atrial natriuretic factor in essential hypertension: relation to cardiac size, function and systemic hemodynamics. J Am Coll Cardiol. 1989 Sep; 14(3):715-24; discussion 725-7.
      View in: PubMed
    20. Bond AL, August P, Druzin ML, Atlas SA, Sealey JE, Laragh JH. Atrial natriuretic factor in normal and hypertensive pregnancy. Am J Obstet Gynecol. 1989 May; 160(5 Pt 1):1112-6.
      View in: PubMed
    21. Laragh JH, Atlas SA. Atrial natriuretic hormone: a regulator of blood pressure and volume homeostasis. Kidney Int Suppl. 1988 Sep; 25:S64-71.
      View in: PubMed
    22. Cody RJ, Atlas SA, Laragh JH. Renal responses to atrial natriuretic factor in patients with congestive heart failure. Eur Heart J. 1988 Jun; 9 Suppl H:29-33.
      View in: PubMed
    23. Volpe M, DeLuca N, Atlas SA, Camargo MJ, Indolfi C, Lembo G, Trimarco B, Condorelli M, Laragh JH. Reduction of atrial natriuretic factor circulating levels by endogenous sympathetic activation in hypertensive patients. Circulation. 1988 May; 77(5):997-1002.
      View in: PubMed
    24. Epstein M, Loutzenhiser R, Friedland E, Aceto RM, Camargo MJ, Atlas SA. Relationship of increased plasma atrial natriuretic factor and renal sodium handling during immersion-induced central hypervolemia in normal humans. J Clin Invest. 1987 Mar; 79(3):738-45.
      View in: PubMed
    25. Atlas SA, Maack T. Effects of atrial natriuretic factor on the kidney and the renin-angiotensin-aldosterone system. Endocrinol Metab Clin North Am. 1987 Mar; 16(1):107-43.
      View in: PubMed
    26. Bosl GJ, Leitner SP, Atlas SA, Sealey JE, Preibisz JJ, Scheiner E. Altered renin and aldosterone excretion in patients treated for metastatic germ cell tumours. Int J Androl. 1987 Feb; 10(1):353-7.
      View in: PubMed
    27. Volpe M, Mele AF, De Luca N, Golino P, Bondiolotti G, Camargo MJ, Atlas SA, Trimarco B. Carotid baroreceptor unloading decreases plasma atrial natriuretic factor in hypertensive patients. J Hypertens Suppl. 1986 Dec; 4(6):S519-22.
      View in: PubMed
    28. Cody RJ, Atlas SA, Laragh JH, Kubo SH, Covit AB, Ryman KS, Shaknovich A, Pondolfino K, Clark M, Camargo MJ, et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest. 1986 Nov; 78(5):1362-74.
      View in: PubMed
    29. Bosl GJ, Leitner SP, Atlas SA, Sealey JE, Preibisz JJ, Scheiner E. Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors. J Clin Oncol. 1986 Nov; 4(11):1684-9.
      View in: PubMed
    30. Atlas SA, Volpe M, Sosa RE, Laragh JH, Camargo MJ, Maack T. Effects of atrial natriuretic factor on blood pressure and the renin-angiotensin-aldosterone system. Fed Proc. 1986 Jun; 45(7):2115-21.
      View in: PubMed
    31. Kleinert HD, Volpe M, Odell G, Marion D, Atlas SA, Camargo MJ, Laragh JH, Maack T. Cardiovascular effects of atrial natriuretic factor in anesthetized and conscious dogs. Hypertension. 1986 Apr; 8(4):312-6.
      View in: PubMed
    32. Sosa RE, Volpe M, Marion DN, Atlas SA, Laragh JH, Vaughan ED, Maack T. Relationship between renal hemodynamic and natriuretic effects of atrial natriuretic factor. Am J Physiol. 1986 Mar; 250(3 Pt 2):F520-4.
      View in: PubMed
    33. Laragh JH, Cody RJ, Covit AB, Atlas SA. The renin system and atrial natriuretic hormone in congestive heart failure. Acta Med Scand Suppl. 1986; 707:45-53.
      View in: PubMed
    34. Atlas SA, Laragh JH. Atrial natriuretic peptide: a new factor in hormonal control of blood pressure and electrolyte homeostasis. Annu Rev Med. 1986; 37:397-414.
      View in: PubMed
    35. Sosa RE, Volpe M, Marion DN, Glorioso N, Laragh JH, Vaughan ED, Maack T, Atlas SA. Effect of atrial natriuretic factor on renin secretion, plasma renin and aldosterone in dogs with acute unilateral renal artery constriction. J Hypertens Suppl. 1985 Dec; 3(3):S299-302.
      View in: PubMed
    36. Volpe M, Odell G, Kleinert HD, Müller F, Camargo MJ, Laragh JH, Maack T, Vaughan ED, Atlas SA. Effect of atrial natriuretic factor on blood pressure, renin, and aldosterone in Goldblatt hypertension. Hypertension. 1985 May-Jun; 7(3 Pt 2):I43-8.
      View in: PubMed
    37. Kubo SH, Cody RJ, Laragh JH, Prida XE, Atlas SA, Yuan Z, Sealey JE. Immediate converting-enzyme inhibition with intravenous enalapril in chronic congestive heart failure. Am J Cardiol. 1985 Jan 1; 55(1):122-6.
      View in: PubMed
    38. Maack T, Marion DN, Camargo MJ, Kleinert HD, Laragh JH, Vaughan ED, Atlas SA. Effects of auriculin (atrial natriuretic factor) on blood pressure, renal function, and the renin-aldosterone system in dogs. Am J Med. 1984 Dec; 77(6):1069-75.
      View in: PubMed
    39. Volpe M, Odell G, Kleinert HD, Camargot MJ, Laragh JH, Lewicki JA, Maack T, Vaughan ED, Atlas SA. Antihypertensive and aldosterone-lowering effects of synthetic atrial natriuretic factor in renin-dependent renovascular hypertension. J Hypertens Suppl. 1984 Dec; 2(3):S313-5.
      View in: PubMed
    40. Atlas SA, Case DB, Yu ZY, Laragh JH. Hormonal and metabolic effects of angiotensin converting enzyme inhibitors. Possible differences between enalapril and captopril. Am J Med. 1984 Aug 20; 77(2A):13-7.
      View in: PubMed
    41. Kleinert HD, Maack T, Atlas SA, Januszewicz A, Sealey JE, Laragh JH. Atrial natriuretic factor inhibits angiotensin-, norepinephrine-, and potassium-induced vascular contractility. Hypertension. 1984 Mar-Apr; 6(2 Pt 2):I143-7.
      View in: PubMed
    42. Atlas SA, Hesson TE, Sealey JE, Dharmgrongartama B, Laragh JH, Ruddy MC, Aurell M. Characterization of inactive renin ("prorenin") from renin-secreting tumors of nonrenal origin. Similarity to inactive renin from kidney and normal plasma. J Clin Invest. 1984 Feb; 73(2):437-47.
      View in: PubMed
    43. Cody RJ, Laragh JH, Atlas SA, Case DB. Converting enzyme inhibition to identify and treat renin-mediated or sodium-volume related forms of increased peripheral resistance in hypertension and in congestive heart failure. J Hypertens Suppl. 1983 Oct; 1(1):77-84.
      View in: PubMed
    44. Cody RJ, Laragh JH, Case DB, Atlas SA. Renin system activity as a determinant of response to treatment in hypertension and heart failure. Hypertension. 1983 Sep-Oct; 5(5 Pt 2):III36-42.
      View in: PubMed
    45. Sealey JE, Atlas SA, Laragh JH. Prorenin in plasma and kidney. Fed Proc. 1983 Jul; 42(10):2681-9.
      View in: PubMed
    46. Atlas SA, Niarchos AP, Case DB. Inhibitors of the renin-angiotensin system. Effects on blood pressure, aldosterone secretion and renal function. Am J Nephrol. 1983 Mar-Jun; 3(2-3):118-27.
      View in: PubMed
    47. Atlas SA, Sealey JE, Hesson TE, Kaplan AP, Ménard J, Corvol P, Laragh JH. Biochemical similarity of partially purified inactive renins from human plasma and kidney. Hypertension. 1982 May-Jun; 4(3 Pt 2):86-95.
      View in: PubMed
    48. Laragh JH, Sealey JE, Atlas SA. The renin system for understanding human hypertension: evidence for blood pressure control by a bipolar vasoconstriction-volume mechanism. Prorenin as a determinant of renin secretion. Clin Exp Hypertens A. 1982; 4(11-12):2303-37.
      View in: PubMed
    49. Atlas SA, Case DB, Sealey JE, Laragh JH. Relationship between plasma renin and cortisol in hypertensive patients. Clin Sci (Lond). 1981 Dec; 61 Suppl 7:265s-268s.
      View in: PubMed
    50. Atlas SA, Case DB. Renin in essential hypertension. Clin Endocrinol Metab. 1981 Nov; 10(3):537-75.
      View in: PubMed
    51. Case DB, Atlas SA, Sullivan PA, Laragh JH. Acute and chronic treatment of severe and malignant hypertension with the oral angiotensin-converting enzyme inhibitor captopril. Circulation. 1981 Oct; 64(4):765-71.
      View in: PubMed
    52. Atlas SA, Sealey JE, Dharmgrongartama B, Hesson TE, Laragh JH. Detection and isolation of inactive, large molecular weight renin in human kidney and plasma. Hypertension. 1981 May-Jun; 3(3 Pt 2):I30-40.
      View in: PubMed
    53. Case DB, Atlas SA, Laragh JH, Sullivan PA, Sealey JE. Use of first-dose response or plasma renin activity to predict the long-term effect of captopril: identification of triphasic pattern of blood pressure response. J Cardiovasc Pharmacol. 1980 Jul-Aug; 2(4):339-46.
      View in: PubMed
    54. Laragh JH, Case DB, Atlas SA, Sealey JE. Captopril compared with other antirenin system agents in hypertensive patients: its triphasic effects on blood pressure and its use to identify and treat the renin factor. Hypertension. 1980 Jul-Aug; 2(4):586-93.
      View in: PubMed
    55. Case DB, Atlas SA, Laragh JH. Reactive hyper-reninaemia to angiotensin blockade identifies renovascular hypertension. Clin Sci (Lond). 1979 Dec; 57 Suppl 5:313s-316s.
      View in: PubMed
    56. Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN. Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natruiresis. Hypertension. 1979 May-Jun; 1(3):274-80.
      View in: PubMed
    57. Sealey JE, Atlas SA, Laragh JH, Oza NB, Ryan JW. Activation of a prorenin-like substance in human plasma by trypsin and by urinary kallikrein. Hypertension. 1979 May-Jun; 1(3):179-89.
      View in: PubMed
    58. Case DB, Atlas SA, Laragh JH, Sealey JE, Sullivan PA, McKinstry DN. Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients. Prog Cardiovasc Dis. 1978 Nov-Dec; 21(3):195-206.
      View in: PubMed
    59. Atlas SA, Sealey JE, Laragh JH, Moon C. Plasma renin and "prorenin" in essential hypertension during sodium depletion, beta-blockade, and reduced arterial pressure. Lancet. 1977 Oct 15; 2(8042):785-9.
      View in: PubMed
    60. Drayer JI, Weber MA, Atlas SA, Laragh JH. Phentolamine testing for alpha adrenergic participation in hypertensive patients: independence from from renin profiles. Clin Pharmacol Ther. 1977 Sep; 22(3):286-92.
      View in: PubMed
    Atlas's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067